Clopidogrel for Long-Term Secondary Prevention After Coronary Artery Stenting
- PMID: 38171707
- DOI: 10.1016/j.jacc.2023.11.004
Clopidogrel for Long-Term Secondary Prevention After Coronary Artery Stenting
Keywords: clopidogrel; drug-eluting stent; dual antiplatelet therapy.
Conflict of interest statement
Funding Support and Author Disclosures Dr Bellemain-Appaix has received lecture fees from Novartis, Biotronik, AstraZeneca, and BMS/Pfizer. Dr Montalescot has received research funds for the Institution or consulting/lecture fees from Abbott, Amgen, AstraZeneca, Ascendia, Bayer, BMS, Boehringer Ingelheim, Boston Scientific, Celecor, CSL Behring, Idorsia, Lilly, Novartis, Novo, Opalia, Pfizer, Quantum Genomics, Sanofi, and Terumo.
Comment on
-
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention.J Am Coll Cardiol. 2024 Jan 2;83(1):17-31. doi: 10.1016/j.jacc.2023.10.013. Epub 2023 Oct 23. J Am Coll Cardiol. 2024. PMID: 37879491 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources